ZD-4190 is a compound that inhibits both the vascular endothelial growth factor receptor 2 (VEGFR2) and the epidermal growth factor receptor (EGFR) signaling pathways, utilized in cancer treatment.

ZD4190能在肿瘤负荷低于临界阈值时，阻止恶性细胞的扩散。

ZD4190 (100 mg/kg, p.o.) 在小鼠中有效延迟了MDA-MB-435肿瘤的生长。在ZD4190处理的肿瘤中，18F-FPPRGD2的摄取相较于基线在第1天显著下降了26.74±8.12%（p<0.05），在第3天下降了41.19±6.63%（p<0.01），然后在第7天恢复到基线水平。ZD4190治疗开始后的第1天和第3天，肿瘤的18F-FLT摄取也有所下降。然而，与对照组比较，ZD4190对肿瘤中18F-FDG的摄取没有显著影响。

ZD4190 was administered by gavage suspended in 1% polysorbate 80 at 50 mg/kg 24 h after tumour cell implantation for a maximum of 22 days. Control rodents were gavaged with the vehicle only and a third group was untreated. In preliminary experiments, rodents were killed on alternate days so that the effect of ZD4190 on tumour outgrowth could be assessed and subsequently the treatment response was evaluated at day 9 or 22. At least five rodents were included in each treatment group.